Roger Dansey, M.D.
Director

Roger Dansey, M.D., currently serves on the Boards of Directors of Inovio Inc. and Ottimo Pharma. Previously, he was interim chief oncology officer and chief development officer of Pfizer Oncology. Dr. Dansey also served as chief medical officer and president of research and development at Seagen prior to Pfizer’s acquisition of the company. Earlier in his career, he held senior leadership positions at Merck, Gilead Sciences and Amgen. Dr. Dansey played a key role in the development and approvals of numerous important cancer therapies, including Keytruda^® (pembrolizumab), Xgeva^®/Prolia^® (denosumab), Zydelig^® (idelalisib), Adcetris^® (brentuximab vedotin), Padcev^® (enfortumab vedotin), Tivdak^® (tisotumab vedotin) and Tukysa^® (tucatinib). He holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa, and before joining industry, he was an associate professor of hematology/oncology at the Karmanos Cancer Institute in Detroit.